New combo therapy aims to save bladders from cancer
NCT ID NCT07307456
Summary
This study is testing whether adding a new immunotherapy drug (toripalimab) to a standard bladder cancer treatment (BCG) can better control high-risk bladder cancer. The goal is to help patients avoid having their bladder surgically removed. The study will enroll 31 patients to see how well the combination works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ChangHai Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.